Back to top

Analyst Blog

Sanofi’s (SNY - Analyst Report) Aubagio is currently marketed in the U.S. as a once-daily treatment for patients with relapsing forms of multiple sclerosis. Aubagio is also approved in several other regions including the EU, Australia, Argentina, Chile, South Korea, and Mexico. In the second quarter of 2013, Aubagio generated sales of €33 million compared with €20 million in the first quarter of 2013. We believe that Aubagio possesses significant commercialization opportunity.

The company announced positive data from the two-year, double-blind, multi-center TOPIC (n = 618) study evaluating Aubagio. It was found that the use of Aubagio 14mg resulted in a 35% reduction in the risk of a new clinical relapse or MRI lesion as compared to placebo.

Additionally, the increase in total lesion volume was 5% in the Aubagio 14mg arm as compared to 28% in the placebo arm. However, Aubagio 7mg failed to show statistically significant difference from placebo on certain endpoints.

We note that apart from Aubagio, currently available oral multiple sclerosis therapies include Novartis’ (NVS - Analyst Report) Gilenya and Biogen Idec’s (BIIB - Analyst Report) Tecfidera. Competition in the oral multiple sclerosis market is intense and Aubagio needs to demonstrate superior efficacy and tolerability to gain share.

Sanofi carries a Zacks Rank #4 (Sell). We are concerned about the generic erosion confronting most of Sanofi’s key drugs. Additionally pipeline failures (oncology candidate -- iniparib and anticoagulant -- otamixaban) have put immense pressure on Sanofi’s pipeline.

Right now, Allergan Inc. (AGN - Analyst Report) looks more attractive in the pharma space with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.71 +4.51%
WEATHERFORD… WFT 23.75 +3.66%
BANCO DO BR… BDORY 14.46 +3.66%
EQT MIDSTRE… EQM 97.64 +2.85%
GREEN PLAIN… GPRE 45.01 +2.74%